ArticleVirchows Archiv : an international journal of pathology2026
Malignant struma ovarii: clinicopathological and molecular features in a series of nine cases.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Malignant struma ovarii (MSO) represents a rare form of ovarian tumor, necessitating further refinement in both classification systems and management approaches. In this study, we aimed to delineate the clinicopathological and molecular characteristics of MSO while assessing the utility of the World Health Organization (WHO) 2022 thyroid tumor classification framework for its diagnostic subtyping and clinical management. We analyzed MSO cases through comprehensive histopathology, immunohistochemistry (IHC), and targeted next-generation sequencing (NGS). The nine MSO cases comprised three papillary thyroid carcinomas (PTC; one follicular variant), four follicular thyroid carcinomas (FTC), one oncocytic (Hürthle cell) carcinoma (OCA), and one differentiated high-grade thyroid carcinoma (DHGTC). All tumors were unilateral and FIGO stage I. The patients (median age 59, range 23-73 years) most often presented with an adnexal mass or abdominal pain. Histologically, all cases showed thyroid-type carcinoma arising within a teratomatous ovary. IHC demonstrated universal thyroid differentiation (TTF-1, thyroglobulin, PAX8 +) and typical thyroid carcinoma markers (CK19, HBME1, galectin-3) in most cases, and frequent CD56 loss. Molecular analysis of eight successful sequencing tumors revealed NRAS Q61 or HRAS Q61 mutations in three cases and a rare BRAF exon 11 (p.G469A) mutation in one PTC case. Novel EIF1AX/PTEN/KMT2C/BRCA1 alterations were identified in four cases. No TERT promoter mutations or RET/PTC fusions were detected. Tumors were assigned into RAS-like (5/8) and BRAF-like category (2/8) per WHO 2022 criteria; the remaining one tumor had no specifical mutations or related profiles. Clinically, all patients remain disease-free after surgery (follow-up 4-120 months). In conclusions, MSO shares histomolecular overlap with primary thyroid carcinoma, validating WHO 2022 thyroid tumor classification for risk stratification in struma ovarii. Conservative surgical management achieves excellent outcomes in low-grade cases.
Indexed as
Identifiers
41087724What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.